Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan
- 15 August 2007
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 22 (9) , 1494-1499
- https://doi.org/10.1111/j.1440-1746.2006.04539.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2005
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004
- Practical difficulties in the management of hepatitis B in the Asia–Pacific regionJournal of Gastroenterology and Hepatology, 2004
- EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B13–14 September, 2002Geneva, SwitzerlandJournal of Hepatology, 2003
- Chronic hepatitis BHepatology, 2001
- Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in KoreaHepatology, 2000
- Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis BPharmacoEconomics, 2000
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Cost-effectiveness of Interferon-α2b Treatment for Hepatitis B e Antigen-Positive Chronic Hepatitis BAnnals of Internal Medicine, 1995
- Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infectionGastroenterology, 1987